Online citations, reference lists, and bibliographies.
← Back to Search

Elicitation Of Utility Scores In Canada For Immune Thrombocytopenia Treated With Romiplostim Or Watch And Rescue

M. Iskedjian, A. Tinmouth, D. Arnold, R. Deuson, J. Isitt, J. Mikhael
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Abstract Objectives: The objective of this study was to obtain utilities, or preference-based quality-of-life values, from the Canadian general public, for potential health states experienced by immune thrombocytopenia (ITP) patients receiving either romiplostim (a new thrombopoietin mimetic agent) or ‘watch and rescue’ therapy. Utilities are needed to conduct a cost-utility analysis of romiplostim for formulary and reimbursement decisions. Methods: An electronic Time Trade-off (TTO) survey was developed and administered to a sample of the general public in Canada, with 12 distinct health states derived from two randomized clinical trials of romiplostim vs watch and rescue treatment. Two pilot tests assessed interpretability and respondent burden. In the final survey, each subject was administered the TTO for four randomly-selected health states. Descriptive statistics were computed for utility scores, and differences between health states were evaluated with an analysis of variance model. Results: Eight hundred and twenty-one adults completed the TTO survey. Mean age was 36.4 (SD = 15) years; 63% were female. Mean (SD) utility scores ranged from 0.476 (0.271) for the most severe health state (significant bleeding) to 0.633 (0.282) for the least severe health state depicting successful treatment with romiplostim. Statistical significance was found on the mean difference between the most severe health state and five other health states (p < 0.05). After adjusting utilities for matching Canadian demographic parameters, no substantial difference was found between original utility scores and adjusted scores. Conclusions: This study provides evidence of the Canadian general public’s preference for 12 ITP health states pertaining to romiplostim treatment or watch and rescue. This study had a number of limitations, the main ones being the lack of perfect match in demographics between this sample and the Canadian population, as well as the fact that the scenario descriptions were based on both published literature and expert opinion. Despite those limitations, the obtained utility scores may be used in cost-utility models of romiplostim as a treatment for ITP patients in Canada.
This paper references
Thrombocytopenia. I. Incidence and aetiology.
L. E. Böttiger (1972)
10.1016/0021-9681(78)90072-3
The utility of different health states as perceived by the general public.
D. Sackett (1978)
10.1016/S0140-6736(85)91244-9
INCIDENCE AND AETIOLOGY OF MELANOMA
L. Gordon (1985)
10.1016/0021-9681(87)90019-1
Utility approach to measuring health-related quality of life.
G. Torrance (1987)
10.1016/0895-4356(89)90039-5
Methodology for measuring health-state preferences--I: Measurement strategies.
D. Froberg (1989)
10.1017/S026646230000979X
Protein A immunoadsorption column versus splenectomy in the treatment of steroid-resistant immune thrombocytopenic purpura. A cost-effectiveness analysis.
K. Kunz (1996)
10.1093/acprof:oso/9780190492939.001.0001
Cost-effectiveness in health and medicine
M. Gold (1996)
Identifying and Valuing Outcomes
D. Patrick (1996)
10.1182/BLOOD.V94.3.909.415K02_909_913
The incidence of idiopathic thrombocytopenic purpura in adults increases with age.
H. Frederiksen (1999)
10.1177/009286150003400119
User Preferences for Computer Administration of Quality of Life Instruments*
J. Crawley (2000)
10.1001/ARCHINTE.160.11.1630
The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts.
Yoram Cohen (2000)
10.1592/phco.20.17.1390.34887
Evaluating Health‐Related Quality of Life: Cost Comparison of Computerized Touch‐Screen Technology and Traditional Paper Systems
J. Lofland (2000)
10.1182/BLOOD.V97.9.2549
Morbidity and mortality in adults with idiopathic thrombocytopenic purpura.
J. Portielje (2001)
10.1056/NEJMRA010501
Immune thrombocytopenic purpura.
D. Cines (2002)
10.1046/j.1365-2141.2002.03669.x
Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults
D. Provan (2002)
10.1046/j.1365-2141.2003.04547.x
Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population‐based cohort of 245 patients
A. J. Neylon (2003)
10.1053/APMR.2003.50245
Health outcomes assessment in vulnerable populations: measurement challenges and recommendations.
E. Hahn (2003)
10.1097/00043426-200301000-00011
Development of Disease-Specific Health-Related Quality-of-Life Instruments for Children With Immune Thrombocytopenic Purpura and Their Parents
D. Barnard (2003)
10.1023/A:1022017130014
Adjusting distributions of the Health Utilities Index Mark 3 utility scores of health-related quality of life
Jian Sun (2004)
10.1017/S1462399404008415
Chronic idiopathic thrombocytopenic purpura (ITP): molecular mechanisms and implications for therapy.
P. Andersson (2004)
10.1017/S1462399404007963
The discovery and role of ADAM33, a new candidate gene for asthma.
J. Holloway (2004)
10.1111/J.1365-2257.2005.00702.X
Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura.
K. Ramadan (2005)
10.1111/j.1651-2227.2005.tb01887.x
Childhood idiopathic thrombocytopenic purpura in the Nordic countries: Epidemiology and predictors of chronic disease
B. Zeller (2005)
10.1002/9781118445112.stat04913
Time Trade-Off Technique †
A. Gafni (2005)
10.1146/ANNUREV.MED.56.082103.104644
Management of adult idiopathic thrombocytopenic purpura.
D. Cines (2005)
10.1016/J.CLIM.2006.04.573
Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura.
H. Ren (2006)
10.1093/RHEUMATOLOGY/KEI100
Touch-screen computer systems in the rheumatology clinic offer a reliable and user-friendly means of collecting quality-of-life and outcome data from patients with rheumatoid arthritis.
M. C. Greenwood (2006)
10.1186/1477-7525-5-11
A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: Its development and validation
S. Mathias (2007)
10.1016/j.clinthera.2007.05.005
A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial.
S. Mathias (2007)
10.7326/0003-4819-146-1-200701020-00006
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
D. Arnold (2007)
10.1002/pbc.20830
A cost‐utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP)
Sarah H. O'Brien (2007)
10.1186/1477-7525-6-13
Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective
S. Mathias (2008)
10.1016/S0084-3954(08)70313-0
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
J. Stockman (2008)
10.1002/AJH.20992
Self‐reported health‐related quality of life in adults with chronic immune thrombocytopenic purpura
R. McMillan (2008)
10.1111/j.1365-2141.2008.07464.x
Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trials
J. George (2009)
10.1182/blood-2008-07-162503
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.
F. Rodeghiero (2009)
10.1185/03007995.2010.494126
Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura
A. Szende (2010)
10.1016/B978-1-4831-6719-0.50010-5
INCIDENCE AND ÆTIOLOGY
V. Cope (2013)
Canadian Agency for Drugs and Technologies in Health. Procedure for common drug review



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar